BPMC Stock Tickeron detected bullish Stock Pattern: Pennant BPMC on May 28, 2025, netting in a 27.36% gain over 1 week

GET DAILY SIGNALS

Get AI intraday signals

BPMC - Blueprint Medicines Corp

Ticker: BPMC

Company: Blueprint Medicines

Gain: +27.36%

Confirmed: 05/28/25

Succeeded: 06/02/25

Total length: 11 days

BPMC sees its 50-day moving average cross bullishly above its 200-day moving average

The 50-day moving average for BPMC moved above the 200-day moving average on June 04, 2025. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on May 29, 2025. You may want to consider a long position or call options on BPMC as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for BPMC just turned positive on June 02, 2025. Looking at past instances where BPMC's MACD turned positive, the stock continued to rise in of 50 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where BPMC advanced for three days, in of 305 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 207 cases where BPMC Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 9 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where BPMC declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

BPMC broke above its upper Bollinger Band on June 02, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. BPMC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (24.155) is normal, around the industry mean (16.972). P/E Ratio (0.000) is within average values for comparable stocks, (59.618). BPMC's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (14.472) is also within normal values, averaging (257.692).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.